GAXYQ yields 20000000.00% · JNJ yields 2.13%● Live data
📍 GAXYQ pulled ahead of the other in Year 1
Combined, GAXYQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GAXYQ + JNJ for your $10,000?
Galaxy Next Generation, Inc. manufactures and distributes interactive learning technology hardware and software that allows the presenter and participant to engage in a collaborative instructional environment in the United States. It offers G2 slim interactive flat panel display (IFPD), including interactive panel control and learning software, integrated PC for IFPD, mobile carts, mounts, and accessories for IFPD; G2 communicator bells, paging, and intercom products consisting of G2 Communicator software, cloud or on-premise hosting servers, internet protocol end points of varying solutions, and G2 visual communicators; G2 secure products, such as visual alerts, door hardening and device monitoring products, and chat access with first responders; and classroom audio amplification solutions comprising amplifiers, door hardening monitoring products, student microphones, call switches, and assisted listening devices, as well as various other national and international branded peripheral and communication devices. It also provides installation, training, maintenance, and warranty services. The company was founded in 2001 and is based in Toccoa, Georgia. On May 9, 2024, Galaxy Next Generation, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Georgia.
Full GAXYQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.